Annual Congress Stockholm 2002

Saturday, 14.09.2002
Sunday, 15.09.2002
Monday, 16.09.2002
Tuesday, 17.09.2002
Wednesday, 18.09.2002

Citations should be made in the following way: Authors. Title. Eur Respir J 2002; 20: Suppl. 38, abstract number.

Material from 2002:

3388 Abstracts
6 Slide presentations
5 Handouts

Material from 2002: Show

Community-acquired pneumonia - aetiology and management

Oral Presentation
Chairs: M. A. Woodhead (Manchester, United Kingdom), W. Boersma (Oudorp, The Netherlands)

Download all media

Residual pulmonary abnormalities after L. pneumophila pneumonia: risk factors, radiological findings and functional disturbances R. E. Jonkers, K. D. Lettinga, O. M. van Delden, C. M. Roos, P. Speelman, H. M. Jansen (Amsterdam, The Netherlands)
Factors associated with unknown aetiology in patients with community-acquired pneumonia T. Bauer, S. Ewig, M. A. Marcos, J. Angrill, A. Rano, A. de Roux, J. Mensa, J. A. Martinez, J. Puig de la Bellacasa, A. Torres (Bochum, Bonn, Germany; Barcelona, Spain)
Community-acquired pneumonia (CAP) in alcoholic patients (AL): differences in aetiology and severity A. de Roux, E. Garcia, M. A. Marcos, R. Estruch, P. Mensa, A. Torres (Barcelona, Spain)
Validation of indices and predictive rules of severity for community-acquired pneumonia S. Ewig, A. de Roux, J. Mensa, M. A. Marcos, M. Niederman, A. Torres (Bonn, Germany; Barcelona, Spain; New York, United States Of America)
Discharge delay in patients with community-acquired pneumonia (CAP) treated with a pneumonia critical pathway J. J. Moeller, M. Ma, P. Hernandez, T. Marrie, W. Patrick (Halifax, Edmonton, Canada)
Earlier discharge of patients treated with moxifloxacin IV/PO monotherapy (MXF) versus amoxicillin/clavulanate (AMC) ±] clarithromycin (CLA) for community-acquired pneumonia (CAP) results in cost savings to the German and French healthcare M. Drummond, D. Becker, M. Hux, J. Chancellor, I. Duprat-Lomon, P. P. Sagnier (Heslington, Amersham, Stoke Court/Stoke Poges, United Kingdom; Burlington, Canada; Puteaux, France)
Telithromycin is effective in the treatment of high-risk patients with community-acquired pneumonia L. Hagberg, S. Jenkins, R. Nusrat (Goteborg, Sweden; Bridgewater, United States Of America)
Telithromycin is as effective as comparator antibacterials in the treatment of lower respiratory tract infections M. Zervos, S. Jenkins, R. Nusrat (Royal Oak, Bridgewater, United States Of America)